Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
08/30/2021 - 08:30 AM
SOMERSET, N.J. --(BUSINESS WIRE)--
Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10 . Ying Huang , Chief Executive Officer and Chief Financial Officer, will represent the Company in a session scheduled at 8:45 a.m. (Eastern Time) .
The webcast will be available to investors and other interested parties by accessing the Legend Biotech website at https://investors.legendbiotech.com .
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 900 employees across the United States , China and Europe , along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.
View source version on businesswire.com : https://www.businesswire.com/news/home/20210830005070/en/
Investor Contacts:
Jessie Yeung , Head of Corporate Finance and Investor Relations, Legend Biotech
jessie.yeung@legendbiotech.com or investor@legendbiotech.com
Crystal Chen , Manager of Investor Relations and Corporate Communications, Legend Biotech
crystal.chen@legendbiotech.com
Press Contact:
Tina Carter , Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com or media@legendbiotech.com
Source: Legend Biotech
LEGN Rankings
#704 Ranked by Stock Gains
LEGN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Commercial Services, Miscellaneous Commercial Services, Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
United States
City
Somerset
About LEGN
legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o
